Clinical Trial Update: Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate for liver metastases from gastrointestinal stromal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Conditions: Gastrointestinal Stromal Tumor, Metastatic Cancer | Phase 2 | Status: COMPLETED